drugset / Trial / NCT05671445
The Study of CM326 in Adult Subjects With Atopic Dermatitis
NaSingle-groupOpen-labelTreatment
Summary
This is a open-label, multi-center study to evaluate the safety and efficacy of CM326 in atopic adrmatitis subjects.
Timeline
- Start
- 2023-02-09
- Primary completion
- 2024-03-28
- Completion
- 2025-03-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OCANKITUG | Monoclonal antibody | — | Subcutaneous |